SPY332.11+2.05 0.62%
DIA272.00+3.59 1.34%
IXIC10,998.40+57.23 0.52%

Cue Biopharma Begins Dosing Cohort 5 In An Ongoing Phase 1 Monotherapy Trial Of CUE-101 In HPV+ Recurrent/Metastatic Head And Neck Cancer

Benzinga · -